Values First Advisors Inc. Purchases Shares of 1,507 Rapport Therapeutics (NASDAQ:RAPP)

Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics (NASDAQ:RAPP) during the third quarter, Holdings Channel reports. The institutional investor acquired 1,507 shares of the company’s stock, valued at approximately $31,000.

Several other hedge funds have also modified their holdings of RAPP. SG Americas Securities LLC purchased a new stake in Rapport Therapeutics during the 3rd quarter worth about $101,000. Sandia Investment Management LP purchased a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $116,000. Davidson Kempner Capital Management LP acquired a new stake in Rapport Therapeutics in the second quarter valued at approximately $229,000. Squarepoint Ops LLC purchased a new position in Rapport Therapeutics in the second quarter worth approximately $380,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Rapport Therapeutics during the 2nd quarter worth approximately $1,757,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective for the company. Stifel Nicolaus initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target for the company. Finally, TD Cowen started coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a “buy” rating on the stock.

Rapport Therapeutics Stock Down 2.5 %

Shares of NASDAQ:RAPP opened at $24.22 on Friday. The business’s 50 day moving average is $21.48. Rapport Therapeutics has a twelve month low of $16.55 and a twelve month high of $29.74.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.02). On average, equities research analysts forecast that Rapport Therapeutics will post -3.46 EPS for the current year.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.